Products Press Releases Partnering Careers Contact

Featured Post

Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada

January 13, 2026

June 3, 2021

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

May 4, 2021

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets)

January 5, 2021

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets)

October 28, 2020

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

August 26, 2020

KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity

August 18, 2020

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada